OFS Credit Company (NASDAQ:OCCI) reported a contraction in its net asset value and a decline in quarterly investment income for its fiscal second quarter, driven by yield compression and weaker cash flow dynamics across its structured credit holdings.
TG Therapeutics (NASDAQ:TGTX) reported positive topline results from an early-stage clinical evaluation of a subcutaneous formulation of its flagship therapy, BRIUMVI, in patients with myasthenia gravis, marking a significant milestone in the company’s strategy to expand the drug's utility beyond its approved indication for multiple sclerosis.
RedHill Biopharma (NASDAQ:RDHL) announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation to its investigational asset, opaganib, for the treatment of neuroblastoma, a type of cancer that primarily affects infants and young children.
Invivyd (NASDAQ:IVVD) has initiated dosing in its LIBERTY Phase 3 clinical trial, a randomized, double-blind study designed to evaluate the safety, tolerability, and immunology of its investigational monoclonal antibody candidate, VYD2311, alone and co-administered with an mRNA COVID-19 vaccine in healthy adults.
Alterity Therapeutics (NASDAQ:ATHE) has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), securing critical regulatory alignment on the design of its upcoming pivotal Phase 3 clinical program for lead candidate ATH434.
Lands' End (NASDAQ:LE) reported a substantial swing to first-quarter net profitability due to a major brand management transaction, shielding the company's bottom line from a drop in core e-commerce and retail revenue.
SailPoint (NASDAQ:SAIL) reported a 22% increase in first-quarter revenue, driven by robust enterprise adoption of its software-as-a-service identity management platforms amid tightening regulatory mandates for corporate data security.
CECO Environmental (NASDAQ:CECO) raised its full-year 2026 financial guidance, factoring in the initial operational contributions from its recently finalized acquisition of Thermon Group Holdings.
United Natural Foods (NYSE:UNFI) reported a return to profitability for the third quarter of fiscal year 2026, as targeted overhead reductions and warehouse optimization measures successfully offset a moderate contraction in top-line sales.
The J.M. Smucker Company (NYSE:SJM) reported a 20% increase in fourth-quarter adjusted earnings per share, driven by favorable pricing actions and portfolio management, while issuing a forward-looking forecast that projects a modest revenue contraction for the upcoming fiscal year.
Titan Machinery (NASDAQ:TITN) reported a double-digit decline in first-quarter revenue, swinging to a net loss as a broader cyclical slowdown in global agricultural and construction markets continues to weigh on heavy equipment retail volumes.
Burning Rock Biotech (NASDAQ:BNR) reported an 18.9% drop in first-quarter revenue for fiscal year 2026, as lower volumes across its core diagnostic testing and pharmaceutical services lines countered ongoing cost-containment measures.
